221 related articles for article (PubMed ID: 26719543)
1. IMPORTANCE OF APOPTOSIS MARKERS (MDM2, BCL-2 AND Bax) IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER.
Saker Z; Tsintsadze O; Jiqia I; Managadze L; Chkhotua A
Georgian Med News; 2015 Dec; (249):7-14. PubMed ID: 26719543
[TBL] [Abstract][Full Text] [Related]
2. Expression of p27((Kip1)), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells.
Nikoleishvili D; Pertia A; Trsintsadze O; Gogokhia N; Managadze L; Chkhotua A
Int Urol Nephrol; 2008; 40(4):953-9. PubMed ID: 18317945
[TBL] [Abstract][Full Text] [Related]
3. IMPORTANCE OF APOPTOSIS MARKERS (MDM2, BCL-2 AND Bax) IN CONVENTIONAL RENAL CELL CARCINOMA.
Saker Z; Tsintsadze O; Jiqia I; Managadze L; Chkhotua A
Georgian Med News; 2015 Dec; (249):27-33. PubMed ID: 26719546
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.
Iacopino F; Angelucci C; Lama G; Zelano G; La Torre G; D'Addessi A; Giovannini C; Bertaccini A; Macaluso MP; Martorana G; Sica G
Anticancer Res; 2006; 26(3A):1849-54. PubMed ID: 16827116
[TBL] [Abstract][Full Text] [Related]
5. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins.
Tang DG; Li L; Chopra DP; Porter AT
Cancer Res; 1998 Aug; 58(15):3466-79. PubMed ID: 9699682
[TBL] [Abstract][Full Text] [Related]
6. The role of FASL, BCL-2 and BAX polymorphisms in brazilian patients with prostate cancer and benign prostatic hyperplasia.
da Silva Lawisch GK; Biolchi V; Kaufmann G; Nicolai G; Capitaneo E; Rosembach TR; Zang J; Brum IS; Chies JAB
Mol Biol Rep; 2022 Oct; 49(10):9445-9451. PubMed ID: 35988104
[TBL] [Abstract][Full Text] [Related]
7. Reverse transcriptase-PCR analysis of apoptosis-regulating gene expression in human benign prostatic hyperplasia.
Angelucci C; Iacopino F; Lama G; Zelano G; Gianesini G; Sica G; Bono AV
Anticancer Res; 2005; 25(6B):3937-41. PubMed ID: 16309180
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades.
Nikoleishvili D; Pertia A; Tsintsadze O; Gogokhia N; Chkhotua A
Georgian Med News; 2007 Feb; (143):34-8. PubMed ID: 17404436
[TBL] [Abstract][Full Text] [Related]
9. Apoptotic and predictive factors by Bax, Caspases 3/9, Bcl-2, p53 and Ki-67 in prostate cancer after 12 Gy single-dose.
Pisani C; Ramella M; Boldorini R; Loi G; Billia M; Boccafoschi F; Volpe A; Krengli M
Sci Rep; 2020 Apr; 10(1):7050. PubMed ID: 32341393
[TBL] [Abstract][Full Text] [Related]
10. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y
J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
[TBL] [Abstract][Full Text] [Related]
11. Effect of Beclin-1 gene silencing on autophagy and apoptosis of the prostatic hyperplasia epithelial cells.
Liu R; Zhang S; Wan R; Deng J; Fang W
Clinics (Sao Paulo); 2022; 77():100076. PubMed ID: 36088885
[TBL] [Abstract][Full Text] [Related]
12. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
[TBL] [Abstract][Full Text] [Related]
13. Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels.
Tucker CA; Kapanen AI; Chikh G; Hoffman BG; Kyle AH; Wilson IM; Masin D; Gascoyne RD; Bally M; Klasa RJ
Mol Cancer Ther; 2008 Apr; 7(4):749-58. PubMed ID: 18375822
[TBL] [Abstract][Full Text] [Related]
14. Deregulation of miR-10b and miR-21 Correlate with Cancer Stem Cells Expansion through the Apoptotic Pathway in Prostate Cancer.
Shukla KK; Choudhary GR; Sankanagoudar S; Misra S; Vishnoi JR; Pareek P; Pilla KK; Pandey SN; Sharma P
Asian Pac J Cancer Prev; 2023 Jun; 24(6):2105-2119. PubMed ID: 37378942
[TBL] [Abstract][Full Text] [Related]
15. Abnormalities of apoptotic and cell cycle regulatory proteins in distinct histopathologic components of benign prostatic hyperplasia.
Gandour-Edwards R; Mack PC; Devere-White RW; Gumerlock PH
Prostate Cancer Prostatic Dis; 2004; 7(4):321-6. PubMed ID: 15314639
[TBL] [Abstract][Full Text] [Related]
16. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R
Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic versus proliferative activities in human benign prostatic hyperplasia.
Kyprianou N; Tu H; Jacobs SC
Hum Pathol; 1996 Jul; 27(7):668-75. PubMed ID: 8698310
[TBL] [Abstract][Full Text] [Related]
18. Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis.
Jin BR; An HJ
Aging (Albany NY); 2020 Feb; 12(3):2142-2155. PubMed ID: 32018227
[TBL] [Abstract][Full Text] [Related]
19. Qianliening capsule treats benign prostatic hyperplasia via induction of prostatic cell apoptosis.
Zheng H; Xu W; Lin J; Peng J; Hong Z
Mol Med Rep; 2013 Mar; 7(3):848-54. PubMed ID: 23314795
[TBL] [Abstract][Full Text] [Related]
20. MMP26: A potential biomarker for prostate cancer.
Cheng T; Li F; Wei R; Lv MQ; Zhou Y; Dai Y; Yuan Y; Jiang GY; Ma D; Gao QL
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):891-894. PubMed ID: 29270749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
